ABIVAX
€83.50Change from previous close: −0.77%Absolute change: −€0.65
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -52.0 | -50.5 | -23.2 | -71.3 | -33.3 | — |
| Depreciation and amortization | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | — |
| Capital expenditure | -0.1 | -0.1 | -0.1 | — | -0.0 | -0.0 |
| Investing cash flow | 1.0 | 0.5 | -12.7 | 3.3 | 0.2 | — |
| Financing cash flow | -39.3 | 0.1 | -39.6 | 603 | -8.8 | — |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Debt issued | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Debt repaid | -0.2 | -0.4 | -40.8 | -5.7 | -6.9 | — |
| Effect of exchange rates | -4.5 | 10.7 | -1.3 | -7.2 | -1.2 | — |
| Net change in cash | -84.9 | -50.0 | -71.7 | 536 | -41.5 | — |
| Free cash flow | -52.1 | -50.6 | -23.3 | -71.3 | -33.4 | — |